rs2395029, HCP5

N. diseases: 12
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Psoriasis
CUI: C0033860
Disease: Psoriasis
0.820 GeneticVariation BEFREE The results demonstrated that SNPs rs2395029, rs17728338 and rs610604 from the HCP5, TNIP1 and TNFAIP3 genes, respectively, were associated with psoriasis in the studied population at both genotype level and allelic level (P < 0.05). 25264125 2014
Psoriasis
CUI: C0033860
Disease: Psoriasis
0.820 GeneticVariation GWASCAT However, rs2395029 encoding the G2V polymorphism within the class I gene HCP5 (combined P = 2.13x10(-26) in U.S. cases) yielded the highest ORs with both PS and PSA (4.1 and 3.2 respectively). 18369459 2008
Psoriasis
CUI: C0033860
Disease: Psoriasis
0.820 GeneticVariation BEFREE However, rs2395029 encoding the G2V polymorphism within the class I gene HCP5 (combined P = 2.13x10(-26) in U.S. cases) yielded the highest ORs with both PS and PSA (4.1 and 3.2 respectively). 18369459 2008
Psoriasis
CUI: C0033860
Disease: Psoriasis
0.820 GeneticVariation GWASDB However, rs2395029 encoding the G2V polymorphism within the class I gene HCP5 (combined P = 2.13x10(-26) in U.S. cases) yielded the highest ORs with both PS and PSA (4.1 and 3.2 respectively). 18369459 2008
Chemical and Drug Induced Liver Injury
CUI: C4277682
Disease: Chemical and Drug Induced Liver Injury
0.800 GeneticVariation GWASCAT Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. 30661239 2019
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
CUI: C1836232
Disease: ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
0.800 GeneticVariation GWASDB The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
AIDS, PROGRESSION TO
CUI: C1836233
Disease: AIDS, PROGRESSION TO
0.800 GeneticVariation GWASCAT The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
CUI: C1836230
Disease: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
0.800 GeneticVariation GWASDB The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
AIDS, PROGRESSION TO
CUI: C1836233
Disease: AIDS, PROGRESSION TO
0.800 GeneticVariation GWASDB The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
CUI: C1836232
Disease: ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
0.800 GeneticVariation GWASCAT The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
HIV-1, RESISTANCE TO
CUI: C1836231
Disease: HIV-1, RESISTANCE TO
0.800 GeneticVariation GWASCAT The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
HIV-1, RESISTANCE TO
CUI: C1836231
Disease: HIV-1, RESISTANCE TO
0.800 GeneticVariation GWASDB The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
CUI: C1836230
Disease: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
0.800 GeneticVariation GWASCAT The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 21051598 2010
HIV-1, RESISTANCE TO
CUI: C1836231
Disease: HIV-1, RESISTANCE TO
0.800 GeneticVariation GWASDB Common genetic variation and the control of HIV-1 in humans. 20041166 2009
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
CUI: C1836232
Disease: ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
0.800 GeneticVariation GWASDB Common genetic variation and the control of HIV-1 in humans. 20041166 2009
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
CUI: C1836230
Disease: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
0.800 GeneticVariation GWASDB Common genetic variation and the control of HIV-1 in humans. 20041166 2009
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
CUI: C1836232
Disease: ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
0.800 GeneticVariation GWASCAT Common genetic variation and the control of HIV-1 in humans. 20041166 2009
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
CUI: C1836230
Disease: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
0.800 GeneticVariation GWASCAT Common genetic variation and the control of HIV-1 in humans. 20041166 2009
Acquired Immunodeficiency Syndrome
CUI: C0001175
Disease: Acquired Immunodeficiency Syndrome
0.800 GeneticVariation GWASDB Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). 19115949 2009
AIDS, PROGRESSION TO
CUI: C1836233
Disease: AIDS, PROGRESSION TO
0.800 GeneticVariation GWASDB Common genetic variation and the control of HIV-1 in humans. 20041166 2009
Acquired Immunodeficiency Syndrome
CUI: C0001175
Disease: Acquired Immunodeficiency Syndrome
0.800 GeneticVariation GWASCAT Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). 19115949 2009
Chemical and Drug Induced Liver Injury
CUI: C4277682
Disease: Chemical and Drug Induced Liver Injury
0.800 GeneticVariation GWASDB HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. 19483685 2009
AIDS, PROGRESSION TO
CUI: C1836233
Disease: AIDS, PROGRESSION TO
0.800 GeneticVariation GWASCAT Common genetic variation and the control of HIV-1 in humans. 20041166 2009
HIV-1, RESISTANCE TO
CUI: C1836231
Disease: HIV-1, RESISTANCE TO
0.800 GeneticVariation GWASCAT Common genetic variation and the control of HIV-1 in humans. 20041166 2009
Chemical and Drug Induced Liver Injury
CUI: C4277682
Disease: Chemical and Drug Induced Liver Injury
0.800 GeneticVariation GWASCAT HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. 19483685 2009